• Ocular Therapeutix reported its fourth-quarter and full-year 2025 results on 5 February 2026, with quarterly revenue falling to US$13.25 million and annual revenue to US$51.95 million, alongside wider annual net losses versus the prior year.
• Amid this weaker top line, the company still reported loss per share in line with the prior-year quarter and moved ahead with key clinical programs and a new equity plan for employee incentives.
• Next, we’ll examine how the revenue shortfall against expectations shapes Ocular Therapeutix’s investment narrative over the coming period.

AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Ocular Therapeutix's Investment Narrative?

For anyone considering Ocular Therapeutix today, the investment case really hinges on belief in its ophthalmology pipeline, particularly the upcoming SOL-1 data for AXPAXLI in wet AMD, rather than current financials. The latest quarterly miss on revenue and the wider full-year loss reinforce how dependent the story is on future trial readouts and eventual commercialization, not near-term profitability. At the same time, loss per share matched the prior-year quarter and the company is still moving its Phase 3 programs forward, while the new employee equity plan and ESOP-related shelf registration highlight a continued focus on retaining talent despite dilution concerns. The sharp share price pullback since the start of the year suggests the market is already weighing these risks heavily, but it does not fundamentally change the central catalyst: clinical outcomes over the next few years.

Ocular Therapeutix's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Simply Wall St Community members put Ocular Therapeutix’s fair value anywhere from almost zero to very large US$ per share across 5 different views, underlining just how far apart opinions can be. Set that against the recent revenue shortfall, rising losses and reliance on pivotal trial outcomes, and you can see why it is worth comparing several perspectives before deciding how that uncertainty fits into your own expectations for the business.

Explore 5 other fair value estimates on Ocular Therapeutix - why the stock might be worth over 9x more than the current price!

Build Your Own Ocular Therapeutix Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Ocular Therapeutix research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Ocular Therapeutix research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ocular Therapeutix's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.